<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Atrial fibrillation in adults: Use of oral anticoagulants</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Atrial fibrillation in adults: Use of oral anticoagulants</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Atrial fibrillation in adults: Use of oral anticoagulants</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Warren J Manning, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Daniel E Singer, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Gregory YH Lip, MD, FRCPE, FESC, FACC</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Peter J Zimetbaum, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Scott E Kasner, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Bradley P Knight, MD, FACC</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Susan B Yeon, MD, JD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Sep 25, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Most patients with atrial fibrillation (AF) should receive long-term oral anticoagulation to decrease the risk of ischemic stroke and other embolic events. For most patients, the benefit from anticoagulation outweighs the associated increase in the risk of bleeding.</p><p>The use of anticoagulant therapy for patients with AF who are not pregnant (excluding those with rheumatic mitral stenosis that is moderate or severe [mitral valve area ≤1.5 cm<sup>2</sup>], a bioprosthetic valve within three to six months of implantation, or a mechanical heart valve) will be reviewed here. Management for patients with valve disease is briefly discussed in a section below that provides links to related topics on these specific valve conditions. (See <a class="local">'Patients with valvular heart disease'</a> below.)</p><p>Related topics include:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/128998.html" rel="external">"Atrial fibrillation in adults: Selection of candidates for anticoagulation"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Anticoagulation for atrial fibrillation during pregnancy. (See  <a class="medical medical_review" href="/z/d/html/13600.html" rel="external">"Supraventricular arrhythmias during pregnancy", section on 'Atrial fibrillation and flutter'</a> and  <a class="medical medical_review" href="/z/d/html/1342.html" rel="external">"Use of anticoagulants during pregnancy and postpartum"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/906.html" rel="external">"Prevention of embolization prior to and after restoration of sinus rhythm in atrial fibrillation"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/1059.html" rel="external">"Stroke in patients with atrial fibrillation"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/928.html" rel="external">"Atrial fibrillation: Left atrial appendage occlusion"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph utd-adt-cnt utd-adt-pathwys">●</span><span class="utd-adt-cnt utd-adt-pathwys utd-content-120056">(Related Pathway(s):  <a class="utd-content-120056" href="/pathway/120056?topicRef=1031&amp;source=see_link">Atrial fibrillation: Anticoagulation for adults with atrial fibrillation</a>.)</span></p><p></p><p class="headingAnchor" id="H124798703"><span class="h1">APPROACH TO ANTICOAGULATION</span></p><p class="headingAnchor" id="H2876030080"><span class="h2">Choice of anticoagulant</span><span class="headingEndMark"> — </span>For patients with AF, we suggest the following sequential steps:</p><p class="bulletIndent1"><span class="glyph">●</span>Determine if anticoagulation is indicated. The identification of patients who should receive long-term oral anticoagulation is discussed separately. Prior to initiation of anticoagulant therapy, possible contraindications should be weighed  (<a class="graphic graphic_table graphicRef107527" href="/z/d/graphic/107527.html" rel="external">table 1</a>). (See  <a class="medical medical_review" href="/z/d/html/128998.html" rel="external">"Atrial fibrillation in adults: Selection of candidates for anticoagulation"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Select an anticoagulant. The following discussion applies to patients who are not pregnant. Selection of anticoagulant for use during pregnancy is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/13600.html" rel="external">"Supraventricular arrhythmias during pregnancy", section on 'Anticoagulation'</a> and  <a class="medical medical_review" href="/z/d/html/1342.html" rel="external">"Use of anticoagulants during pregnancy and postpartum"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For most patients with AF with an indication for anticoagulation, we recommend a direct oral anticoagulant (DOAC) rather than vitamin K antagonist (VKA; eg, <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a>).</p><p></p><p class="bulletIndent2">For most patients with AF who have been treated with <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a> with an annual time in the therapeutic range (TTR) of at least 70 percent, we suggest consideration of switching to a DOAC. However, it is reasonable to continue VKA in these patients for financial or other preferences.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Exceptions to the general preference for use of DOAC rather than VKA in patients with AF with an indication for anticoagulation include:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Clinical settings in which VKA (eg, <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a>; target international normalized ratio [INR] 2.0 to 3.0; TTR ≥70 percent) is the agent of choice and in which DOAC should not be used (see <a class="local">'Patients with valvular heart disease'</a> below):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Patients with a mechanical heart valve of any type and location. (See  <a class="medical medical_review" href="/z/d/html/8171.html" rel="external">"Antithrombotic therapy for mechanical heart valves"</a>.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Patients with rheumatic mitral stenosis that is severe or clinically significant (mitral valve area ≤1.5 cm<sup>2</sup>). (See  <a class="medical medical_review" href="/z/d/html/8139.html" rel="external">"Rheumatic mitral stenosis: Overview of management", section on 'Prevention of thromboembolism'</a>.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Patients for whom the DOAC agents are avoided due to drug interactions (eg, those receiving P-glycoprotein drug efflux pump [P-gp] inducers, which can decrease the anticoagulant effect of DOACs and chronic antiviral agents, which may increase the anticoagulant effect of DOACs)  (<a class="graphic graphic_table graphicRef112756 graphicRef76992 graphicRef73326" href="/z/d/graphic/112756.html" rel="external">table 2A-C</a>) [<a href="#rid1">1</a>]. (See <a class="local">'Drug interactions'</a> below and  <a class="medical medical_review" href="/z/d/html/1370.html" rel="external">"Direct oral anticoagulants (DOACs) and parenteral direct-acting anticoagulants: Dosing and adverse effects"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Clinical settings in which VKA is reasonable or preferable to DOAC:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For patients who are not likely to comply with the twice daily dosing of <a class="drug drug_general" data-topicid="8926" href="/z/d/drug information/8926.html" rel="external">dabigatran</a> or <a class="drug drug_general" data-topicid="85642" href="/z/d/drug information/85642.html" rel="external">apixaban</a> and who are unable to take once-a-day <a class="drug drug_general" data-topicid="9498" href="/z/d/drug information/9498.html" rel="external">rivaroxaban</a> or <a class="drug drug_general" data-topicid="99275" href="/z/d/drug information/99275.html" rel="external">edoxaban</a> due to intolerance.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For patients for whom the DOAC agents will lead to an unacceptable increase in patient cost.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For patients with chronic severe kidney disease whose creatinine clearance (CrCl by Cockcroft-Gault equation) is less than 25 to 30 mL/min. VKA is generally preferred in this setting, although some clinicians prescribe <a class="drug drug_general" data-topicid="85642" href="/z/d/drug information/85642.html" rel="external">apixaban</a> for selected patients in this setting, as described below. (See <a class="local">'Chronic kidney disease'</a> below.)</p><p></p><p><span class="utd-adt-cnt utd-adt-pathwys utd-content-120056">(Related Pathway(s):  <a class="utd-content-120056" href="/pathway/120056?topicRef=1031&amp;source=see_link">Atrial fibrillation: Anticoagulation for adults with atrial fibrillation</a>.)</span></p><p>Evidence supporting this approach comes from randomized trials in patients with nonvalvular AF in which DOAC use resulted in similar or lower rates of both ischemic stroke and major bleeding compared with treatment with adjusted-dose <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a> (INR of 2.0 to 3.0)  (<a class="graphic graphic_table graphicRef131871" href="/z/d/graphic/131871.html" rel="external">table 3</a>) [<a href="#rid2">2-8</a>]. Important additional advantages of the DOAC agents include a high relative but small absolute reduction in the risk of intracranial hemorrhage (ICH), convenience (no requirement for routine testing of the INR), lack of susceptibility to dietary interactions, and markedly reduced susceptibility to drug interactions [<a href="#rid3">3-6</a>]. Disadvantages of DOAC include lack of efficacy and safety data in patients with severe chronic kidney disease, lack of easily available monitoring of blood levels and compliance, and higher patient cost in some health care settings. (See  <a class="medical medical_review" href="/z/d/html/128998.html" rel="external">"Atrial fibrillation in adults: Selection of candidates for anticoagulation", section on 'Chronic kidney disease'</a>.)</p><p>A meta-analysis including the RE-LY (<a class="drug drug_general" data-topicid="8926" href="/z/d/drug information/8926.html" rel="external">dabigatran</a>) [<a href="#rid3">3,9</a>], ARISTOTLE (<a class="drug drug_general" data-topicid="85642" href="/z/d/drug information/85642.html" rel="external">apixaban</a>) [<a href="#rid5">5</a>], ROCKET AF (<a class="drug drug_general" data-topicid="9498" href="/z/d/drug information/9498.html" rel="external">rivaroxaban</a>) [<a href="#rid4">4</a>], and ENGAGE AF-TIMI 48 (<a class="drug drug_general" data-topicid="99275" href="/z/d/drug information/99275.html" rel="external">edoxaban</a>) [<a href="#rid10">10</a>] trials supports the broad conclusion that DOAC agents are preferable to adjusted-dose VKA for most patients [<a href="#rid2">2</a>]. Compared with VKA (<a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a>), DOAC reduced rates of mortality, stroke or systemic embolic event, and hemorrhagic stroke  (<a class="graphic graphic_table graphicRef131871" href="/z/d/graphic/131871.html" rel="external">table 3</a>).</p><p>Regarding the relative efficacy and safety of the DOAC agents, no randomized controlled trials (RCTs) directly comparing the DOACs have been published. Published observational studies have many limitations and are no substitute for head to head RCTs [<a href="#rid11">11-16</a>].</p><p class="headingAnchor" id="H124798709"><span class="h2">Initiation</span></p><p class="headingAnchor" id="H434020150"><span class="h3">DOAC</span><span class="headingEndMark"> — </span>For patients with AF starting DOAC, effective anticoagulation is achieved within a few hours. We do not use heparin to bridge patients starting DOAC. For patients prescribed one of the DOACs, we suggest that clinicians review dosing recommendations from regulatory agencies and available in drug information compendia such as Lexicomp. (See <a class="local">'Dosing'</a> below.)</p><p class="headingAnchor" id="H3436315773"><span class="h3">Vitamin K antagonist</span><span class="headingEndMark"> — </span>Protocols for initiating VKA (eg, <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a>) are discussed separately. All patients should have an INR measured before starting therapy. (See  <a class="medical medical_review" href="/z/d/html/1334.html" rel="external">"Warfarin and other VKAs: Dosing and adverse effects", section on 'Warfarin administration'</a> and <a class="local">'Dosing'</a> below.)</p><p>For patients with AF starting VKA (eg, <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>With <strong>no </strong>intracardiac thrombus or prior history of thromboembolism, the risk of a thromboembolic event during the several days typically required to achieve therapeutic anticoagulation with <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a> is generally very low. Thus, it is reasonable for outpatients to initiate warfarin without low molecular weight heparin bridging. (See  <a class="medical medical_review" href="/z/d/html/1334.html" rel="external">"Warfarin and other VKAs: Dosing and adverse effects"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>With <strong>high risk </strong>of thromboembolism (eg, <strong>prior</strong> cerebrovascular event/transient ischemic attack or current intracardiac thrombus) and low risk of ICH, initiation of <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a> with a heparin bridging regimen may be reasonable in some clinical settings (eg, patient who is hospitalized for another condition such as heart failure and has <strong>no</strong> acute stroke) although there is no high quality evidence to support this approach.</p><p></p><p class="bulletIndent1">Management for patients <strong>with acute stroke</strong> is discussed below. (See <a class="local">'Acute stroke'</a> below.)</p><p></p><p class="headingAnchor" id="H124799958"><span class="h2">Dosing</span></p><p class="headingAnchor" id="H535082484"><span class="h3">DOACs</span><span class="headingEndMark"> — </span>Dosing recommendations for DOACs are largely derived from the doses tested in the randomized clinical trials  (<a class="graphic graphic_table graphicRef131871" href="/z/d/graphic/131871.html" rel="external">table 3</a>) [<a href="#rid3">3-5,10,17,18</a>]. Given differences in the characteristics and availability of DOACs, it is important for practitioners to develop familiarity with the clinical use of multiple DOAC agents. DOACs are generally administered at fixed doses without laboratory monitoring. Use in patients with chronic kidney disease is discussed below. (See <a class="local">'Chronic kidney disease'</a> below.)</p><p>Use of these agents including drug interactions  (<a class="graphic graphic_table graphicRef112756 graphicRef76992 graphicRef73326" href="/z/d/graphic/112756.html" rel="external">table 2A-C</a>) and dosing in patients with chronic renal insufficiency is presented separately. (See  <a class="medical medical_review" href="/z/d/html/1370.html" rel="external">"Direct oral anticoagulants (DOACs) and parenteral direct-acting anticoagulants: Dosing and adverse effects", section on 'Direct factor Xa inhibitors'</a> and  <a class="medical medical_review" href="/z/d/html/1370.html" rel="external">"Direct oral anticoagulants (DOACs) and parenteral direct-acting anticoagulants: Dosing and adverse effects", section on 'Direct thrombin inhibitors'</a>.):</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="85642" href="/z/d/drug information/85642.html" rel="external">Apixaban</a> – The dose of apixaban is 5 mg twice daily (approximately 12 hours apart) unless the patient has two or more of the following: age ≥80 years, body weight ≤60 kg, or serum creatinine level ≥1.5 mg/dL [133 micromol/L]). Then the dose of apixaban is 2.5 mg twice daily. This dose adjustment is for moderate renal impairment. Data are lacking to inform use in patients with CrCL &lt;15 mL/min or on dialysis. (See <a class="local">'Chronic kidney disease'</a> below.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dabigatran</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with CrCl &gt;30 mL/min, the dose is 150 mg twice daily (approximately 12 hours apart). For most patients prescribed <a class="drug drug_general" data-topicid="8926" href="/z/d/drug information/8926.html" rel="external">dabigatran</a>, we suggest the 150 mg twice daily dose, as opposed to the 110 mg dose, based upon the results of the RE-LY trial. Where available, the 110 mg twice daily dose may be preferred in patients assessed to be at increased risk of bleeding or who are particularly concerned about the risk of bleeding. (See  <a class="medical medical_review" href="/z/d/html/1370.html" rel="external">"Direct oral anticoagulants (DOACs) and parenteral direct-acting anticoagulants: Dosing and adverse effects"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with CrCL 15 to 30 mL/min, the dose is 75 mg orally, twice daily. Concomitant use of a P-gp inhibitor or antiviral should be avoided. We generally avoid use of <a class="drug drug_general" data-topicid="8926" href="/z/d/drug information/8926.html" rel="external">dabigatran</a> in this setting. (See <a class="local">'Choice of anticoagulant'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with CrCl &lt;15 mL/min or on dialysis, no dosing recommendations are available. We avoid use of <a class="drug drug_general" data-topicid="8926" href="/z/d/drug information/8926.html" rel="external">dabigatran</a> in this setting. (See <a class="local">'Choice of anticoagulant'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Edoxaban</strong><strong> </strong>dosing varies according to the estimated glomerular filtration rate:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with a Cockcroft-Gault equation CrCl &gt;95 mL/min, <a class="drug drug_general" data-topicid="99275" href="/z/d/drug information/99275.html" rel="external">edoxaban</a> should <strong>not</strong> be used due to lesser efficacy compared with <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a> in preventing stroke in this group due to high renal clearance. For such patients, another DOAC is an alternative.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with a CrCl of &gt;50 to 95 mL/min, an <a class="drug drug_general" data-topicid="99275" href="/z/d/drug information/99275.html" rel="external">edoxaban</a> dose of 60 mg once daily is used.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with a CrCl of 15 to 50 mL/min, the dose is 30 mg once daily.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with a CrCl of &lt;15 mL/min, there are limited data, so <a class="drug drug_general" data-topicid="99275" href="/z/d/drug information/99275.html" rel="external">edoxaban</a> is avoided in these patients.</p><p></p><p>•For patients ≥65 years of age and with at least one of the following characteristics, the dose is 30 mg once daily: weight ≤60 kg or concomitant use of potent P-glycoprotein inhibitors (eg, <a class="drug drug_general" data-topicid="10043" href="/z/d/drug information/10043.html" rel="external">verapamil</a>, <a class="drug drug_general" data-topicid="9846" href="/z/d/drug information/9846.html" rel="external">quinidine</a>). This is based on the study protocol and subgroup analyses of ENGAGE AF-TIMI 48 [<a href="#rid10">10,19</a>].</p><p class="bulletIndent2"><span class="glyph">•</span>For patients with advanced age (≥80 years) and low body weight (ie, ≤45 kg or ≤60 kg plus an additional risk factor), a lower dose of <a class="drug drug_general" data-topicid="99275" href="/z/d/drug information/99275.html" rel="external">edoxaban</a> (15 mg once daily) may be safe and effective. This approach is supported by the results of the ELDERCARE-AF trial in which 984 Japanese patients age 80 years or older were randomly assigned to receive edoxaban 15 mg or placebo daily [<a href="#rid20">20</a>]. The mean body weight of participants was low (50.6±11 kg). All patients were considered inappropriate candidates for standard oral anticoagulant regimens due to one or more of the following concerns: a low CrCL (≥15 and &lt;30 mL/min), a history of bleeding, low body weight (≤45 kg), or use of a nonsteroidal antiinflammatory drug or an antiplatelet drug. The annualized rate of stroke or systemic embolism was 2.3 and 6.7 percent in the two groups, respectively (hazard ratio [HR] 0.34, 95% CI 0.19-0.61), and the rate of major bleeding was 3.3 and 1.8 percent, respectively (HR 1.87, 95% CI 0.90-3.89). ICH was rare in both groups (0.3 and 0.6 percent). In a prespecified subanalysis of this trial, findings were largely similar across different categories of renal dysfunction (ie, mild, moderate, and severe) [<a href="#rid21">21</a>]. (See <a class="local">'Older adults'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Rivaroxaban</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If the CrCl is &gt;50 mL/min, the <a class="drug drug_general" data-topicid="9498" href="/z/d/drug information/9498.html" rel="external">rivaroxaban</a> dose is 20 mg once daily with the largest meal of the day (&gt;500 calories), usually the evening meal.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If the CrCl is 15 to 50 mL/min, the <a class="drug drug_general" data-topicid="9498" href="/z/d/drug information/9498.html" rel="external">rivaroxaban</a> dose is 15 mg once daily with the largest meal of the day (&gt;500 calories).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If the CrCl &lt;15 mL/min, avoid use of <a class="drug drug_general" data-topicid="9498" href="/z/d/drug information/9498.html" rel="external">rivaroxaban</a>. (See <a class="local">'Chronic kidney disease'</a> below.)</p><p></p><p class="headingAnchor" id="H634454675"><span class="h3">Vitamin K antagonist</span><span class="headingEndMark"> — </span>For patients with AF treated with VKA (eg, <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a>), an INR between 2.0 and 3.0 is recommended with an average annual TTR &gt;70 percent [<a href="#rid22">22,23</a>]. This is based upon the increased risk of stroke observed with INR values significantly below 2 (four- to sixfold at an INR of 1.3 compared with an INR of 2 or above) and the increased risk of bleeding associated with INR above 3.0  (<a class="graphic graphic_figure graphicRef65373" href="/z/d/graphic/65373.html" rel="external">figure 1</a>) [<a href="#rid24">24-28</a>]. Dosing of warfarin is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/1334.html" rel="external">"Warfarin and other VKAs: Dosing and adverse effects", section on 'Warfarin administration'</a>.)</p><p>Advanced age (over 74 years) is an independent risk factor for bleeding during anticoagulation as well as a risk factor for stroke. However, we recommend an INR between 2.0 and 3.0 for these patients as well [<a href="#rid28">28</a>].</p><p class="headingAnchor" id="H124798721"><span class="h2">Temporary interruption of anticoagulation</span><span class="headingEndMark"> — </span>Temporary interruption of oral anticoagulation for reasons of bleeding or urgent/elective surgery/invasive procedure results in an increased risk of thromboembolism after the period of effective anticoagulation has ended [<a href="#rid29">29</a>]. The optimal approach to such patients is unclear and likely depends on issues such as baseline thromboembolic risk, duration of anticoagulant interruption, and bleeding risk. These issues are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/1312.html" rel="external">"Perioperative management of patients receiving anticoagulants"</a> and  <a class="medical medical_review" href="/z/d/html/2609.html" rel="external">"Management of anticoagulants in patients undergoing endoscopic procedures"</a> and  <a class="medical medical_review" href="/z/d/html/1342.html" rel="external">"Use of anticoagulants during pregnancy and postpartum"</a> and  <a class="medical medical_review" href="/z/d/html/1324.html" rel="external">"Management of warfarin-associated bleeding or supratherapeutic INR", section on 'Urgent surgery/procedure'</a>.)</p><p>The discussion of the management of anticoagulant therapy in the patient undergoing percutaneous coronary intervention is found separately [<a href="#rid30">30,31</a>]. (See  <a class="medical medical_review" href="/z/d/html/101552.html" rel="external">"Periprocedural management of antithrombotic therapy in patients receiving long-term oral anticoagulation and undergoing percutaneous coronary intervention", section on 'Elective patients'</a>.)</p><p>The reversal of the anticoagulant effect of <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a> and DOAC agents is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1324.html" rel="external">"Management of warfarin-associated bleeding or supratherapeutic INR"</a> and  <a class="medical medical_review" href="/z/d/html/94788.html" rel="external">"Management of bleeding in patients receiving direct oral anticoagulants", section on 'Anticoagulant reversal'</a>.)</p><p class="headingAnchor" id="H1779990912"><span class="h2">Anticoagulant failure</span><span class="headingEndMark"> — </span>Thromboembolic events occur despite adequate anticoagulation in patients with AF. Predictors of these events include (see  <a class="medical medical_review" href="/z/d/html/1082.html" rel="external">"Early antithrombotic treatment of acute ischemic stroke and transient ischemic attack", section on 'Atrial fibrillation'</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Transesophageal echocardiographic (TEE) evidence of dense spontaneous echo contrast and low left atrial appendage ejection velocity [<a href="#rid32">32</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>TEE evidence of complex aortic plaque [<a href="#rid32">32</a>]. TEE-detected thrombi can be related to clinical risk factors [<a href="#rid33">33</a>]. (See  <a class="medical medical_review" href="/z/d/html/14085.html" rel="external">"Pathophysiology of ischemic stroke", section on 'Stroke subtypes'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Subtherapeutic INR on VKA [<a href="#rid34">34</a>] or noncompliance in patients taking DOAC agents.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Elevated D-dimer levels. In a single-center, prospective, observational study of 269 patients, D-dimer levels were elevated (at least 0.5 mcg/mL) in 23 percent, and elevated levels were significantly associated with a higher rate of thromboembolism (HR 15.8, 95% CI 3.33-75.5) [<a href="#rid35">35</a>]. Similarly, in a study of 829 patients with AF, elevated von Willebrand factor levels were associated with risk of thrombotic events [<a href="#rid36">36</a>]. However, we do not recommend routine testing of D-dimer or von Willebrand factor in patients with AF, as incorporating such testing in anticoagulation decision-making has not been shown to alter outcomes in this setting.</p><p></p><p>There are no studies of the optimal anticoagulation strategy for those experiencing a thromboembolic event. For those patients with a subtherapeutic INR with <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a> at the time of the event, an attempt should be made to identify the cause (compliance, drug/food interaction) and to consider switching to a DOAC if the annual TTR has been less than 70 percent [<a href="#rid37">37</a>]. For those on a twice-a-day DOAC, consideration of a once-a-day DOAC should be made if noncompliance is an issue. For those on a once-a-day DOAC, a different once-daily agent may be considered (eg, another once-daily DOAC or possibly warfarin because the INR can be followed). Though reasonable, none of these approaches is of proven benefit.</p><p>Ischemic strokes with nonembolic causes occur in patients with AF as in patients without AF. These are not the target of anticoagulants. Occurrence of such a stroke is not a "failure" of anticoagulation.</p><p class="headingAnchor" id="H433859596"><span class="h2">Other reasons for switching agents</span><span class="headingEndMark"> — </span>Some patients with AF may need to be switched from DOAC agent to VKA, from VKA to DOAC, or between DOAC agents for reasons other than anticoagulant failure (which is discussed above). (See <a class="local">'Anticoagulant failure'</a> above.)</p><p>Reasons for switching from VKA to DOAC:</p><p class="bulletIndent1"><span class="glyph">●</span>As discussed above, most patients with AF treated with VKA should be switched to DOAC. (See <a class="local">'Choice of anticoagulant'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Need for repeated invasive procedures, annual TTR &lt;70 percent, convenience.</p><p></p><p>Possible reasons for switching from DOAC to VKA:</p><p class="bulletIndent1"><span class="glyph">●</span>Out-of-pocket cost</p><p class="bulletIndent1"><span class="glyph">●</span>Development of severe kidney disease (see <a class="local">'Chronic kidney disease'</a> below)</p><p class="bulletIndent1"><span class="glyph">●</span>Development of a contraindication to DOAC use, as discussed above (see <a class="local">'Choice of anticoagulant'</a> above)</p><p></p><p>Information on switching oral agents is provided separately  (<a class="graphic graphic_table graphicRef120639" href="/z/d/graphic/120639.html" rel="external">table 4</a>). (See  <a class="medical medical_review" href="/z/d/html/1370.html" rel="external">"Direct oral anticoagulants (DOACs) and parenteral direct-acting anticoagulants: Dosing and adverse effects", section on 'Transitioning between anticoagulants'</a>.)</p><p>Recommendations for transitioning between DOACs and parenteral anticoagulants, including <a class="drug drug_general" data-topicid="8518" href="/z/d/drug information/8518.html" rel="external">unfractionated heparin</a> and low molecular weight heparin, are available in the individual drug monographs for each DOAC.</p><p class="headingAnchor" id="H849064"><span class="h2">Drug interactions</span><span class="headingEndMark"> — </span>The individual DOACs are in varying degrees eliminated by CYP3A4 metabolism or are substrates of P-glycoprotein (P-gp) efflux pump and subject to pharmacokinetic drug interactions, although fewer in number than <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a> interactions. Drugs that inhibit CYP3A4 metabolism or P-gp efflux can increase DOAC levels (ie, greater anticoagulant effect and bleeding), whereas drugs that are inducers can decrease DOAC effect, which can lead to therapeutic failure. </p><p>A detailed review of the different drug interactions can be found in tables  (<a class="graphic graphic_table graphicRef112756 graphicRef76992 graphicRef73326" href="/z/d/graphic/112756.html" rel="external">table 2A-C</a>) and the <a class="external" href="/drug-interactions">drug interaction program</a> within UpToDate. Additional related content is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1370.html" rel="external">"Direct oral anticoagulants (DOACs) and parenteral direct-acting anticoagulants: Dosing and adverse effects"</a>.)</p><p class="headingAnchor" id="H23"><span class="h1">SPECIFIC PATIENT GROUPS</span></p><p class="headingAnchor" id="H3142371030"><span class="h2">Patients with valvular heart disease</span><span class="headingEndMark"> — </span>The above general considerations regarding choice of anticoagulant (DOAC versus VKA) apply to patients with valvular heart disease (excluding patients with rheumatic mitral stenosis that is severe or clinically significant [mitral valve area ≤1.5 cm<sup>2</sup>], a bioprosthetic valve within three to six months of implantation, or a mechanical heart valve in any location), although the evidence in patients with severe native valve disease is more limited than for the general population of AF patients [<a href="#rid38">38</a>]. (See <a class="local">'Choice of anticoagulant'</a> above.)</p><p>Some patients with valvular lesions (without heart failure), such as mitral valve prolapse, nonrheumatic moderate or severe mitral regurgitation, mitral valve repair (except for the first three to six months postoperatively), or moderate or less aortic valvular conditions, have been enrolled in clinical trials of the DOACs. These trials also included a few patients (with or without heart failure) with severe native valvular conditions who were not scheduled to undergo valve replacement. As an example, in the ARISTOTLE trial, which compared <a class="drug drug_general" data-topicid="85642" href="/z/d/drug information/85642.html" rel="external">apixaban</a> with <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a>  (<a class="graphic graphic_table graphicRef131871" href="/z/d/graphic/131871.html" rel="external">table 3</a>), approximately 26 percent of the patients had a history of moderate or severe valvular heart disease or previous valve surgery (not including placement of a mechanical heart valve) [<a href="#rid39">39</a>]. While these patients had higher rates of stroke and systemic embolism than those without, the benefits of a lower rate of stroke/systemic embolism and major bleeding with apixaban (compared with warfarin) were similar to those without valvular heart disease.</p><p>Approaches to antithrombotic therapy (including anticoagulation) in patients with AF with the following specific valve conditions are discussed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>Rheumatic mitral stenosis that is severe or clinically significant (mitral valve area ≤1.5<sup> </sup>cm<sup>2</sup>). (See  <a class="medical medical_review" href="/z/d/html/8171.html" rel="external">"Antithrombotic therapy for mechanical heart valves"</a> and  <a class="medical medical_review" href="/z/d/html/8139.html" rel="external">"Rheumatic mitral stenosis: Overview of management", section on 'Prevention of thromboembolism'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Mechanical heart valve in any location. (See  <a class="medical medical_review" href="/z/d/html/8171.html" rel="external">"Antithrombotic therapy for mechanical heart valves"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Surgically implanted bioprosthetic valve. The choice of anticoagulant after surgical valve procedures is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/8171.html" rel="external">"Antithrombotic therapy for mechanical heart valves"</a> and <a class="local">'Choice of anticoagulant'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Transcatheter bioprosthetic valve. The choice of anticoagulant after transcatheter valve procedures is discussed separately. (See <a class="local">'Choice of anticoagulant'</a> above and  <a class="medical medical_review" href="/z/d/html/131939.html" rel="external">"Transcatheter aortic valve implantation: Antithrombotic therapy", section on 'General approach'</a> and  <a class="medical medical_review" href="/z/d/html/99943.html" rel="external">"Transcatheter edge-to-edge mitral repair", section on 'Antithrombotic therapy'</a>.)</p><p></p><p class="headingAnchor" id="H685172264"><span class="h2">Older adults</span><span class="headingEndMark"> — </span>For most older patients, including those over the age of 75 years, we prefer DOACs (also referred to as non-vitamin K oral anticoagulants [NOACs]) to <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a> because of the reduced risk of intracranial hemorrhage versus warfarin. Since there are no head to head randomized trials comparing DOACs in this patient group, we do not have a preference for a specific DOAC.</p><p>Dose adjustment should be made if the patient meets relevant criteria such as renal function for the DOAC. The results of the ELDERCARE-AF trial are discussed separately. (See <a class="local">'Dosing'</a> above and <a class="local">'Chronic kidney disease'</a> below.)</p><p class="headingAnchor" id="H3391447120"><span class="h2">Chronic kidney disease</span></p><p class="headingAnchor" id="H3965676469"><span class="h3">Who to anticoagulate</span><span class="headingEndMark"> — </span>Our approach to deciding which AF patients with chronic kidney disease (CKD) to anticoagulate is presented separately. (See  <a class="medical medical_review" href="/z/d/html/128998.html" rel="external">"Atrial fibrillation in adults: Selection of candidates for anticoagulation", section on 'Chronic kidney disease'</a>.)</p><p class="headingAnchor" id="H416912985"><span class="h3">Choice of anticoagulant</span><span class="headingEndMark"> — </span>For patients with AF and CKD stage G2 or G3  (<a class="graphic graphic_figure graphicRef59716" href="/z/d/graphic/59716.html" rel="external">figure 2</a>) treated with oral anticoagulation, most of our contributors choose a DOAC rather than VKA. However, the evidence to support this choice in patients with CKD is limited [<a href="#rid40">40-44</a>]. One contributor prefers VKA in this setting given wider clinical experience.</p><p>For patients with AF and severe kidney disease (stage G4 or G5; estimated glomerular filtration rate &lt;30 mL/min/1.73 m<sup>2</sup>), on dialysis, or with acute renal injury, DOAC is generally avoided and VKA is generally the preferred long-term anticoagulant. Patients with stage 4 and 5 CKD are at higher risk of having unpredictable sudden deterioration in renal function than patients with normal renal function, and such deterioration could cause an abrupt reduction in clearance of a DOAC that depends on renal metabolism. In such a setting, use of an agent such as <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a> that allows for therapeutic drug monitoring may be preferred. An annual time in the therapeutic range of &gt;70 percent is desirable. (See  <a class="medical medical_review" href="/z/d/html/1370.html" rel="external">"Direct oral anticoagulants (DOACs) and parenteral direct-acting anticoagulants: Dosing and adverse effects", section on 'Chronic kidney disease'</a> and  <a class="medical medical_review" href="/z/d/html/1334.html" rel="external">"Warfarin and other VKAs: Dosing and adverse effects", section on 'Monitoring (PT/INR)'</a>.)</p><p>If a DOAC is chosen for a patient with stage 4 or 5 CKD or on dialysis, our contributors prefer <a class="drug drug_general" data-topicid="85642" href="/z/d/drug information/85642.html" rel="external">apixaban</a>, in part because apixaban is less dependent on kidney function for clearance than other DOACs available in the US  (<a class="graphic graphic_table graphicRef112756" href="/z/d/graphic/112756.html" rel="external">table 2A</a>). The support for use of apixaban in these patients is largely based upon our clinical experience and observational studies [<a href="#rid41">41,42</a>]. In a subgroup analysis of the ARISTOTLE trial in patients with creatinine clearance (CrCl) 25 to 30 mL/min, the risk of major bleeding was significantly less with apixaban compared with <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a> (hazard ratio [HR] 0.34, 95% CI 0.14-0.80) [<a href="#rid42">42</a>]. We avoid <a class="drug drug_general" data-topicid="8926" href="/z/d/drug information/8926.html" rel="external">dabigatran</a> in patients with stage 4 or 5 CKD because a high percentage of the drug is renally cleared. These issues are discussed further separately. (See  <a class="medical medical_review" href="/z/d/html/1370.html" rel="external">"Direct oral anticoagulants (DOACs) and parenteral direct-acting anticoagulants: Dosing and adverse effects", section on 'Chronic kidney disease'</a>.)</p><p>Based upon pharmacokinetic modeling, the US Food and Drug Administration approved DOAC dosing for use in selected patients with CKD based upon Cockcroft-Gault CrCl as described above (see <a class="local">'Dosing'</a> above).</p><p class="headingAnchor" id="H3381111056"><span class="h2">Patients at risk for gastrointestinal bleeding</span><span class="headingEndMark"> — </span>Risk factors for gastrointestinal bleeding in patients on oral anticoagulants have been identified. (See  <a class="medical medical_review" href="/z/d/html/119889.html" rel="external">"Risks and prevention of bleeding with oral anticoagulants", section on 'Gastrointestinal'</a>.)</p><p>Choosing <a class="drug drug_general" data-topicid="85642" href="/z/d/drug information/85642.html" rel="external">apixaban</a> or <a class="drug drug_general" data-topicid="8926" href="/z/d/drug information/8926.html" rel="external">dabigatran</a> over <a class="drug drug_general" data-topicid="9498" href="/z/d/drug information/9498.html" rel="external">rivaroxaban</a> or <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a> may be prudent to prevent major bleeding outcomes in AF patients at high risk of gastrointestinal bleeding. In a subgroup analysis of the ARISTOPHANES observational study, 381,054 individuals anticoagulated for nonvalvular AF and who were at high risk of gastrointestinal bleeding were followed for major bleeding outcomes [<a href="#rid45">45</a>]. Compared with warfarin, apixaban and dabigatran were associated with a lower risk of major bleeding (apixaban: HR 0.59, 95% CI 0.56-0.63; dabigatran: HR 0.78, 95% CI 0.70-0.86), whereas rivaroxaban was associated with a higher gastrointestinal bleeding risk (HR 1.11, 95% CI 1.05-1.16).</p><p class="headingAnchor" id="H524844231"><span class="h2">Acute stroke</span><span class="headingEndMark"> — </span>Recommendations for the management (including the role of antithrombotic therapy) of patients with AF with an acute stroke are presented separately. Patients with AF for whom anticoagulant therapy is being considered and who have had an ischemic stroke within 30 days should be referred to a neurologist or other clinician who is experienced in managing antithrombotic care in such patients. Although once widely practiced, early treatment with heparin for patients with AF who have an acute cardioembolic stroke is generally <strong>avoided</strong> as studies have shown that such treatment causes more harm than good (See  <a class="medical medical_review" href="/z/d/html/1059.html" rel="external">"Stroke in patients with atrial fibrillation"</a> and  <a class="medical medical_review" href="/z/d/html/1082.html" rel="external">"Early antithrombotic treatment of acute ischemic stroke and transient ischemic attack", section on 'Atrial fibrillation'</a>.)</p><p class="headingAnchor" id="H485506357"><span class="h2">AF after surgery</span><span class="headingEndMark"> — </span>Approaches to OAC in patients with AF after cardiac surgery and after noncardiac surgery are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1011.html" rel="external">"Atrial fibrillation and flutter after cardiac surgery", section on 'Our approach to postoperative anticoagulation'</a> and  <a class="medical medical_review" href="/z/d/html/113847.html" rel="external">"Atrial fibrillation in patients undergoing noncardiac surgery", section on 'Anticoagulation after surgery'</a>.)</p><p class="headingAnchor" id="H27"><span class="h2">Concomitant antiplatelet therapy</span><span class="headingEndMark"> — </span>For patients with indications for both anticoagulant for AF and for antiplatelet therapy (for a concurrent condition), any potential benefit must take into account an increased risk of bleeding with concomitant antiplatelet and anticoagulant therapy. The combination of antiplatelet and anticoagulant increases the risk of bleeding compared with either alone [<a href="#rid46">46</a>]. (See  <a class="medical medical_review" href="/z/d/html/128998.html" rel="external">"Atrial fibrillation in adults: Selection of candidates for anticoagulation", section on 'Alternatives to anticoagulation'</a>.)</p><p>The potential use of both anticoagulant and antiplatelet therapies in patients with AF is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1535.html" rel="external">"Coronary artery disease patients requiring combined anticoagulant and antiplatelet therapy", section on 'Efficacy and safety'</a> and  <a class="medical medical_review" href="/z/d/html/101.html" rel="external">"Acute coronary syndrome: Oral anticoagulation in medically treated patients"</a> and  <a class="medical medical_review" href="/z/d/html/101552.html" rel="external">"Periprocedural management of antithrombotic therapy in patients receiving long-term oral anticoagulation and undergoing percutaneous coronary intervention", section on 'Elective patients'</a>.)</p><p>The issue of whether <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> is necessary for secondary prevention of cardiovascular disease in patients treated with anticoagulant for AF is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/110006.html" rel="external">"Aspirin for the secondary prevention of atherosclerotic cardiovascular disease"</a>.)</p><p>The impact of antiplatelet therapy on bleeding (and efficacy) outcomes in patients taking either <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a> or <a class="drug drug_general" data-topicid="8926" href="/z/d/drug information/8926.html" rel="external">dabigatran</a> was evaluated in a post-hoc subgroup analysis of the RE-LY trial (see <a class="local">'Choice of anticoagulant'</a> above) in which approximately 40 percent of patients were taking concomitant <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> or <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">clopidogrel</a> at some point during the study [<a href="#rid47">47</a>]. Very few patients were taking two antiplatelet agents and individuals taking <a class="drug drug_general" data-topicid="9533" href="/z/d/drug information/9533.html" rel="external">prasugrel</a> or <a class="drug drug_general" data-topicid="16784" href="/z/d/drug information/16784.html" rel="external">ticagrelor</a> were not enrolled. The following findings were noted:</p><p class="bulletIndent1"><span class="glyph">●</span>In the comparison of <a class="drug drug_general" data-topicid="8926" href="/z/d/drug information/8926.html" rel="external">dabigatran</a> 110 mg twice daily with <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a> for the prevention of ischemic events, antiplatelet therapy did not significantly change the relative risk (dabigatran noninferior to warfarin) of stroke and systemic embolism. With regard to the outcome of major bleeding, the relative risk did not change significantly, but the crude rates of bleeding were higher in those receiving antiplatelet therapy (2.2 versus 2.8 and 3.8 versus 4.8 percent, comparing dabigatran 110 mg with warfarin in the no antiplatelet and antiplatelet groups, respectively).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In the comparison of <a class="drug drug_general" data-topicid="8926" href="/z/d/drug information/8926.html" rel="external">dabigatran</a> 150 mg twice daily with <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a> for the endpoint of ischemic events, there was a nonsignificant decrease in the relative superiority of dabigatran compared with warfarin with the use of antiplatelet therapy (HR 0.52, 95% CI 0.38-0.72 and HR 0.80, 95% CI 0.59-1.08, comparing dabigatran with warfarin in the no antiplatelet and antiplatelet groups, respectively). With regard to the outcome of major bleeding, the relative risk did not change significantly comparing dabigatran 150 mg twice daily with warfarin, but the crude rates of bleeding were higher in those receiving antiplatelet therapy (2.7 versus 2.8 and 4.4 versus 4.8 percent, respectively).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Concomitant use of a single antiplatelet agent significantly increased the risk of major bleeding (HR 1.6), while dual antiplatelet therapy further increased this risk (HR 2.3).</p><p></p><p>This subgroup analysis from RE-LY raises the possibility that in patients with AF treated with both oral anticoagulant and antiplatelet therapy, <a class="drug drug_general" data-topicid="8926" href="/z/d/drug information/8926.html" rel="external">dabigatran</a> might be preferred to <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a> to reduce the absolute risk of major bleeding.</p><p>As discussed separately, neither <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> alone nor in combination with <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">clopidogrel</a> is as effective as <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a> in preventing stroke in patients with AF. (See  <a class="medical medical_review" href="/z/d/html/128998.html" rel="external">"Atrial fibrillation in adults: Selection of candidates for anticoagulation"</a> and  <a class="medical medical_review" href="/z/d/html/128998.html" rel="external">"Atrial fibrillation in adults: Selection of candidates for anticoagulation", section on 'Alternatives to anticoagulation'</a>.)</p><p class="headingAnchor" id="H1304772709"><span class="h1">RECOMMENDATIONS OF OTHERS</span><span class="headingEndMark"> — </span>Recommendations for the use of antithrombotic agents in patients with AF are available from the American Heart Association/American College of Cardiology/Heart Rhythm Society, the European Society of Cardiology, and the American College of Chest Physicians [<a href="#rid23">23,48-51</a>]. In general, we agree with relevant recommendations made in these guidelines.</p><p class="headingAnchor" id="H1883824501"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/112091.html" rel="external">"Society guideline links: Atrial fibrillation"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/112260.html" rel="external">"Society guideline links: Arrhythmias in adults"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/114614.html" rel="external">"Society guideline links: Anticoagulation"</a>.)</p><p class="headingAnchor" id="H14456462"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, “The Basics” and “Beyond the Basics.” The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on “patient info” and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/15327.html" rel="external">"Patient education: Atrial fibrillation (The Basics)"</a> and  <a class="medical medical_basics" href="/z/d/html/16237.html" rel="external">"Patient education: Medicines for atrial fibrillation (The Basics)"</a> and  <a class="medical medical_basics" href="/z/d/html/16265.html" rel="external">"Patient education: Choosing an oral medicine for blood clots (The Basics)"</a> and  <a class="medical medical_basics" href="/z/d/html/86638.html" rel="external">"Patient education: Taking oral medicines for blood clots (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/z/d/html/3431.html" rel="external">"Patient education: Atrial fibrillation (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/z/d/html/689.html" rel="external">"Patient education: Warfarin (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H31"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Type of anticoagulation </strong>– For most patients with atrial fibrillation (AF) with an indication for anticoagulation, we recommend a direct oral anticoagulant (DOAC) rather than a vitamin K antagonist (VKA; eg, <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a>) (<a class="grade" href="https:///uptodate/show/grade_1" rel="external">Grade 1A</a>). (See <a class="local">'Choice of anticoagulant'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Reasons to switch to a DOAC </strong>– For patients with AF who have been treated with <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a> and are comfortable with periodic international normalized ratio (INR) measurement with an annual time in the therapeutic range (TTR) of at least 70 percent, we suggest consideration of switching to DOAC (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>). However, it is reasonable to continue VKA in these patients for issues of patient cost and preference.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>When to use a VKA </strong>– Exceptions to the general preference for use of DOAC rather than VKA in patients with AF with an indication for anticoagulation include (see <a class="local">'Choice of anticoagulant'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Definite reasons to use a VKA </strong>– Clinical settings in which VKA (eg, <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a>; target INR 2.0 to 3.0; annual TTR ≥70 percent) is the agent of choice and in which DOAC should not be used (see <a class="local">'Patients with valvular heart disease'</a> above):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Patients with rheumatic mitral stenosis that is severe or clinically significant (mitral valve area ≤1.5 cm<sup>2</sup>). (See  <a class="medical medical_review" href="/z/d/html/8139.html" rel="external">"Rheumatic mitral stenosis: Overview of management", section on 'Prevention of thromboembolism'</a>.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Patients with mechanical heart valves of any type and any location. (See  <a class="medical medical_review" href="/z/d/html/8171.html" rel="external">"Antithrombotic therapy for mechanical heart valves"</a>.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Patients with a (surgical or transcatheter) bioprosthetic valve implanted within the prior three to six months. (See  <a class="medical medical_review" href="/z/d/html/108265.html" rel="external">"Transcatheter aortic valve implantation: Periprocedural and postprocedural management"</a> and  <a class="medical medical_review" href="/z/d/html/132746.html" rel="external">"Antithrombotic therapy for surgical bioprosthetic valves and surgical valve repair", section on 'Approach for surgical bioprosthetic valves'</a>.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Patients for whom the DOAC agents are avoided due to drug interactions (eg, those receiving P-glycoprotein drug efflux pump inducers, which can decrease the anticoagulant effect of DOACs)  (<a class="graphic graphic_table graphicRef112756 graphicRef76992 graphicRef73326" href="/z/d/graphic/112756.html" rel="external">table 2A-C</a>) or antivirals that may increase the anticoagulant effect of DOACs. (See <a class="local">'Drug interactions'</a> above and  <a class="medical medical_review" href="/z/d/html/1370.html" rel="external">"Direct oral anticoagulants (DOACs) and parenteral direct-acting anticoagulants: Dosing and adverse effects"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Possible reasons to use a VKA </strong>– Clinical settings in which VKA is reasonable or preferable to DOAC:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For patients who are not likely to comply with the twice daily dosing of <a class="drug drug_general" data-topicid="8926" href="/z/d/drug information/8926.html" rel="external">dabigatran</a> or <a class="drug drug_general" data-topicid="85642" href="/z/d/drug information/85642.html" rel="external">apixaban</a> and who are unable to take once-a-day <a class="drug drug_general" data-topicid="9498" href="/z/d/drug information/9498.html" rel="external">rivaroxaban</a> or <a class="drug drug_general" data-topicid="99275" href="/z/d/drug information/99275.html" rel="external">edoxaban</a> due to intolerance.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For patients for whom the DOAC agents will lead to an unacceptable increase in patient cost.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For patients with chronic severe kidney disease whose estimated glomerular filtration rate (Cockcroft-Gault creatinine clearance) is less than 30 mL/min/. VKA is generally preferred in this setting, although some clinicians prescribe <a class="drug drug_general" data-topicid="85642" href="/z/d/drug information/85642.html" rel="external">apixaban</a> for selected patients in this setting. (See <a class="local">'Chronic kidney disease'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Types of DOACs </strong>– DOACs include the oral direct thrombin inhibitor <a class="drug drug_general" data-topicid="8926" href="/z/d/drug information/8926.html" rel="external">dabigatran</a> and direct factor Xa inhibitors (eg, <a class="drug drug_general" data-topicid="85642" href="/z/d/drug information/85642.html" rel="external">apixaban</a>, <a class="drug drug_general" data-topicid="99275" href="/z/d/drug information/99275.html" rel="external">edoxaban</a>, and <a class="drug drug_general" data-topicid="9498" href="/z/d/drug information/9498.html" rel="external">rivaroxaban</a>). DOACs are generally administered at fixed doses without laboratory monitoring. Given differences in the characteristics and availability of DOACs, it is important for clinicians to be familiar with the clinical use of multiple DOAC agents  (<a class="graphic graphic_table graphicRef112756" href="/z/d/graphic/112756.html" rel="external">table 2A</a> and <a class="graphic graphic_table graphicRef131871" href="/z/d/graphic/131871.html" rel="external">table 3</a>). (See <a class="local">'DOACs'</a> above and  <a class="medical medical_review" href="/z/d/html/1370.html" rel="external">"Direct oral anticoagulants (DOACs) and parenteral direct-acting anticoagulants: Dosing and adverse effects", section on 'Clinician familiarity with dosing'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Target INR </strong>– For patients with AF treated with VKA (eg, <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a>), the target INR is between 2.0 and 3.0 with an average annual TTR ≥70 percent. This is based upon the increased risk of stroke observed with INR values significantly below 2 (four- to sixfold at an INR of 1.3 compared with an INR of 2 or above) and the increased risk of bleeding associated with INR above 3.0  (<a class="graphic graphic_figure graphicRef65373" href="/z/d/graphic/65373.html" rel="external">figure 1</a>). (See <a class="local">'Vitamin K antagonist'</a> above and  <a class="medical medical_review" href="/z/d/html/1334.html" rel="external">"Warfarin and other VKAs: Dosing and adverse effects", section on 'Warfarin administration'</a>.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Bellesini M, Bianchin M, Corradi C, et al. Drug-Drug Interactions between Direct Oral Anticoagulants and Hepatitis C Direct-Acting Antiviral Agents: Looking for Evidence Through a Systematic Review. Clin Drug Investig 2020; 40:1001.</a></li><li><a class="nounderline abstract_t">Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014; 383:955.</a></li><li><a class="nounderline abstract_t">Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361:1139.</a></li><li><a class="nounderline abstract_t">Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365:883.</a></li><li><a class="nounderline abstract_t">Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365:981.</a></li><li><a class="nounderline abstract_t">Chatterjee S, Sardar P, Biondi-Zoccai G, Kumbhani DJ. New oral anticoagulants and the risk of intracranial hemorrhage: traditional and Bayesian meta-analysis and mixed treatment comparison of randomized trials of new oral anticoagulants in atrial fibrillation. JAMA Neurol 2013; 70:1486.</a></li><li><a class="nounderline abstract_t">Salazar CA, del Aguila D, Cordova EG. Direct thrombin inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in people with non-valvular atrial fibrillation. Cochrane Database Syst Rev 2014; :CD009893.</a></li><li><a class="nounderline abstract_t">Bruins Slot KM, Berge E. Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation. Cochrane Database Syst Rev 2018; 3:CD008980.</a></li><li class="breakAll">http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2014/022512Orig1s025ltr.pdf (Accessed on December 05, 2018).</li><li><a class="nounderline abstract_t">Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013; 369:2093.</a></li><li><a class="nounderline abstract_t">Schneeweiss S, Gagne JJ, Patrick AR, et al. Comparative efficacy and safety of new oral anticoagulants in patients with atrial fibrillation. Circ Cardiovasc Qual Outcomes 2012; 5:480.</a></li><li><a class="nounderline abstract_t">Lip GYH, Keshishian A, Li X, et al. Effectiveness and Safety of Oral Anticoagulants Among Nonvalvular Atrial Fibrillation Patients. Stroke 2018; 49:2933.</a></li><li><a class="nounderline abstract_t">Graham DJ, Baro E, Zhang R, et al. Comparative Stroke, Bleeding, and Mortality Risks in Older Medicare Patients Treated with Oral Anticoagulants for Nonvalvular Atrial Fibrillation. Am J Med 2019; 132:596.</a></li><li><a class="nounderline abstract_t">Andersson NW, Svanström H, Lund M, et al. Comparative effectiveness and safety of apixaban, dabigatran, and rivaroxaban in patients with non-valvular atrial fibrillation. Int J Cardiol 2018; 268:113.</a></li><li><a class="nounderline abstract_t">Fralick M. Effectiveness and safety of apixaban. Ann Intern Med 2020; :463.</a></li><li><a class="nounderline abstract_t">Ray WA, Chung CP, Stein CM, et al. Association of Rivaroxaban vs Apixaban With Major Ischemic or Hemorrhagic Events in Patients With Atrial Fibrillation. JAMA 2021; 326:2395.</a></li><li><a class="nounderline abstract_t">Connolly SJ, Ezekowitz MD, Yusuf S, et al. Newly identified events in the RE-LY trial. N Engl J Med 2010; 363:1875.</a></li><li><a class="nounderline abstract_t">Connolly SJ, Wallentin L, Ezekowitz MD, et al. The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study. Circulation 2013; 128:237.</a></li><li><a class="nounderline abstract_t">Kato ET, Giugliano RP, Ruff CT, et al. Efficacy and Safety of Edoxaban in Elderly Patients With Atrial Fibrillation in the ENGAGE AF-TIMI 48 Trial. J Am Heart Assoc 2016; 5.</a></li><li><a class="nounderline abstract_t">Okumura K, Akao M, Yoshida T, et al. Low-Dose Edoxaban in Very Elderly Patients with Atrial Fibrillation. N Engl J Med 2020; 383:1735.</a></li><li><a class="nounderline abstract_t">Yoshida T, Nakamura A, Funada J, et al. Efficacy and Safety of Edoxaban 15 mg According to Renal Function in Very Elderly Patients With Atrial Fibrillation: A Subanalysis of the ELDERCARE-AF Trial. Circulation 2022; 145:718.</a></li><li><a class="nounderline abstract_t">Fuster V, Rydén LE, Asinger RW, et al. ACC/AHA/ESC Guidelines for the Management of Patients With Atrial Fibrillation: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the North American Society of Pacing and Electrophysiology. Circulation 2001; 104:2118.</a></li><li><a class="nounderline abstract_t">You JJ, Singer DE, Howard PA, et al. Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e531S.</a></li><li><a class="nounderline abstract_t">Singer DE, Albers GW, Dalen JE, et al. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133:546S.</a></li><li><a class="nounderline abstract_t">Hylek EM, Skates SJ, Sheehan MA, Singer DE. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Engl J Med 1996; 335:540.</a></li><li><a class="nounderline abstract_t">Hylek EM, Go AS, Chang Y, et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med 2003; 349:1019.</a></li><li><a class="nounderline abstract_t">European Atrial Fibrillation Trial Study Group. Optimal oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and recent cerebral ischemia. N Engl J Med 1995; 333:5.</a></li><li><a class="nounderline abstract_t">Singer DE, Chang Y, Fang MC, et al. Should patient characteristics influence target anticoagulation intensity for stroke prevention in nonvalvular atrial fibrillation?: the ATRIA study. Circ Cardiovasc Qual Outcomes 2009; 2:297.</a></li><li><a class="nounderline abstract_t">Sherwood MW, Douketis JD, Patel MR, et al. Outcomes of temporary interruption of rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: results from the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF). Circulation 2014; 129:1850.</a></li><li><a class="nounderline abstract_t">Faxon DP, Eikelboom JW, Berger PB, et al. Consensus document: antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting. A North-American perspective. Thromb Haemost 2011; 106:572.</a></li><li><a class="nounderline abstract_t">Huber K, Airaksinen KJ, Cuisset T, et al. Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting: similarities and dissimilarities between North America and Europe. Thromb Haemost 2011; 106:569.</a></li><li><a class="nounderline abstract_t">Bernhardt P, Schmidt H, Hammerstingl C, et al. Patients with atrial fibrillation and dense spontaneous echo contrast at high risk a prospective and serial follow-up over 12 months with transesophageal echocardiography and cerebral magnetic resonance imaging. J Am Coll Cardiol 2005; 45:1807.</a></li><li><a class="nounderline abstract_t">Tang RB, Dong JZ, Liu XP, et al. Is CHA2DS2-VASc score a predictor of left atrial thrombus in patients with paroxysmal atrial fibrillation? Thromb Haemost 2011; 105:1107.</a></li><li><a class="nounderline abstract_t">Reynolds MW, Fahrbach K, Hauch O, et al. Warfarin anticoagulation and outcomes in patients with atrial fibrillation: a systematic review and metaanalysis. Chest 2004; 126:1938.</a></li><li><a class="nounderline abstract_t">Sadanaga T, Sadanaga M, Ogawa S. Evidence that D-dimer levels predict subsequent thromboembolic and cardiovascular events in patients with atrial fibrillation during oral anticoagulant therapy. J Am Coll Cardiol 2010; 55:2225.</a></li><li><a class="nounderline abstract_t">Roldán V, Marín F, Muiña B, et al. Plasma von Willebrand factor levels are an independent risk factor for adverse events including mortality and major bleeding in anticoagulated atrial fibrillation patients. J Am Coll Cardiol 2011; 57:2496.</a></li><li><a class="nounderline abstract_t">Lip GYH, Banerjee A, Boriani G, et al. Antithrombotic Therapy for Atrial Fibrillation: CHEST Guideline and Expert Panel Report. Chest 2018; 154:1121.</a></li><li><a class="nounderline abstract_t">Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 2021; 143:e72.</a></li><li><a class="nounderline abstract_t">Avezum A, Lopes RD, Schulte PJ, et al. Apixaban in Comparison With Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: Findings From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial. Circulation 2015; 132:624.</a></li><li><a class="nounderline abstract_t">Ha JT, Neuen BL, Cheng LP, et al. Benefits and Harms of Oral Anticoagulant Therapy in Chronic Kidney Disease: A Systematic Review and Meta-analysis. Ann Intern Med 2019; 171:181.</a></li><li><a class="nounderline abstract_t">Siontis KC, Zhang X, Eckard A, et al. Outcomes Associated With Apixaban Use in Patients With End-Stage Kidney Disease and Atrial Fibrillation in the United States. Circulation 2018; 138:1519.</a></li><li><a class="nounderline abstract_t">Stanifer JW, Pokorney SD, Chertow GM, et al. Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Advanced Chronic Kidney Disease. Circulation 2020; 141:1384.</a></li><li><a class="nounderline abstract_t">Weir MR, Ashton V, Moore KT, et al. Rivaroxaban versus warfarin in patients with nonvalvular atrial fibrillation and stage IV-V chronic kidney disease. Am Heart J 2020; 223:3.</a></li><li><a class="nounderline abstract_t">Su X, Yan B, Wang L, et al. Oral Anticoagulant Agents in Patients With Atrial Fibrillation and CKD: A Systematic Review and Pairwise Network Meta-analysis. Am J Kidney Dis 2021; 78:678.</a></li><li><a class="nounderline abstract_t">Lip GYH, Keshishian AV, Zhang Y, et al. Oral Anticoagulants for Nonvalvular Atrial Fibrillation in Patients With High Risk of Gastrointestinal Bleeding. JAMA Netw Open 2021; 4:e2120064.</a></li><li><a class="nounderline abstract_t">Lamberts M, Olesen JB, Ruwald MH, et al. Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fibrillation patients following myocardial infarction and coronary intervention: a nationwide cohort study. Circulation 2012; 126:1185.</a></li><li><a class="nounderline abstract_t">Dans AL, Connolly SJ, Wallentin L, et al. Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial. Circulation 2013; 127:634.</a></li><li><a class="nounderline abstract_t">January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation 2014; 130:e199.</a></li><li><a class="nounderline abstract_t">Heidbuchel H, Verhamme P, Alings M, et al. Updated European Heart Rhythm Association practical guide on the use of non-vitamin-K antagonist anticoagulants in patients with non-valvular atrial fibrillation: Executive summary. Eur Heart J 2016.</a></li><li><a class="nounderline abstract_t">Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J 2021; 42:373.</a></li><li><a class="nounderline abstract_t">January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons. Circulation 2019; 140:e125.</a></li></ol></div><div id="topicVersionRevision">Topic 1031 Version 145.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32809123" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Drug-Drug Interactions between Direct Oral Anticoagulants and Hepatitis C Direct-Acting Antiviral Agents: Looking for Evidence Through a Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24315724" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19717844" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Dabigatran versus warfarin in patients with atrial fibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21830957" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21870978" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Apixaban versus warfarin in patients with atrial fibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24166666" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : New oral anticoagulants and the risk of intracranial hemorrhage: traditional and Bayesian meta-analysis and mixed treatment comparison of randomized trials of new oral anticoagulants in atrial fibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24677203" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Direct thrombin inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in people with non-valvular atrial fibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29509959" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29509959" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24251359" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Edoxaban versus warfarin in patients with atrial fibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22787066" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Comparative efficacy and safety of new oral anticoagulants in patients with atrial fibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30571400" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Effectiveness and Safety of Oral Anticoagulants Among Nonvalvular Atrial Fibrillation Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30639551" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Comparative Stroke, Bleeding, and Mortality Risks in Older Medicare Patients Treated with Oral Anticoagulants for Nonvalvular Atrial Fibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29934230" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Comparative effectiveness and safety of apixaban, dabigatran, and rivaroxaban in patients with non-valvular atrial fibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Effectiveness and safety of apixaban</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34932078" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Association of Rivaroxaban vs Apixaban With Major Ischemic or Hemorrhagic Events in Patients With Atrial Fibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21047252" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Newly identified events in the RE-LY trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23770747" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27207971" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Efficacy and Safety of Edoxaban in Elderly Patients With Atrial Fibrillation in the ENGAGE AF-TIMI 48 Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32865374" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Low-Dose Edoxaban in Very Elderly Patients with Atrial Fibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35226559" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Efficacy and Safety of Edoxaban 15 mg According to Renal Function in Very Elderly Patients With Atrial Fibrillation: A Subanalysis of the ELDERCARE-AF Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11673357" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : ACC/AHA/ESC Guidelines for the Management of Patients With Atrial Fibrillation: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the North American Society of Pacing and Electrophysiology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22315271" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18574273" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8678931" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12968085" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7776995" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Optimal oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and recent cerebral ischemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20031854" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Should patient characteristics influence target anticoagulation intensity for stroke prevention in nonvalvular atrial fibrillation?: the ATRIA study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24552831" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Outcomes of temporary interruption of rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: results from the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21785808" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Consensus document: antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting. A North-American perspective.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21909592" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting: similarities and dissimilarities between North America and Europe.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15936610" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Patients with atrial fibrillation and dense spontaneous echo contrast at high risk a prospective and serial follow-up over 12 months with transesophageal echocardiography and cerebral magnetic resonance imaging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21544316" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Is CHA2DS2-VASc score a predictor of left atrial thrombus in patients with paroxysmal atrial fibrillation?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15596696" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Warfarin anticoagulation and outcomes in patients with atrial fibrillation: a systematic review and metaanalysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20466203" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Evidence that D-dimer levels predict subsequent thromboembolic and cardiovascular events in patients with atrial fibrillation during oral anticoagulant therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21497043" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Plasma von Willebrand factor levels are an independent risk factor for adverse events including mortality and major bleeding in anticoagulated atrial fibrillation patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30144419" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Antithrombotic Therapy for Atrial Fibrillation: CHEST Guideline and Expert Panel Report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33332150" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26106009" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Apixaban in Comparison With Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: Findings From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31307056" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Benefits and Harms of Oral Anticoagulant Therapy in Chronic Kidney Disease: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29954737" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Outcomes Associated With Apixaban Use in Patients With End-Stage Kidney Disease and Atrial Fibrillation in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32160801" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Advanced Chronic Kidney Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32112872" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Rivaroxaban versus warfarin in patients with nonvalvular atrial fibrillation and stage IV-V chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33872690" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Oral Anticoagulant Agents in Patients With Atrial Fibrillation and CKD: A Systematic Review and Pairwise Network Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34398204" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Oral Anticoagulants for Nonvalvular Atrial Fibrillation in Patients With High Risk of Gastrointestinal Bleeding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22869839" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fibrillation patients following myocardial infarction and coronary intervention: a nationwide cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23271794" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24682347" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27282612" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Updated European Heart Rhythm Association practical guide on the use of non-vitamin-K antagonist anticoagulants in patients with non-valvular atrial fibrillation: Executive summary.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32860505" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30686041" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
